NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FPRX stock has decreased by 20.5% and is now trading at $2.33. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Five Prime Therapeutics.

Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Five Prime Therapeutics.

Five Prime Therapeutics Inc (NASDAQ:FPRX) posted its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. The biotechnology company earned $3.21 million during the quarter, compared to analysts' expectations of $4.05 million. Five Prime Therapeutics had a negative net margin of 922.43% and a negative return on equity of 71.29%. View Five Prime Therapeutics' earnings history.

6 analysts have issued 1 year target prices for Five Prime Therapeutics' stock. Their forecasts range from $5.00 to $24.00. On average, they expect Five Prime Therapeutics' share price to reach $12.25 in the next twelve months. This suggests a possible upside of 425.8% from the stock's current price. View analysts' price targets for Five Prime Therapeutics.

Media headlines about FPRX stock have been trending positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutFive Prime Therapeutics.

Five Prime Therapeutics saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 1,422,400 shares, a decrease of 10.5% from the February 27th total of 1,590,000 shares. Based on an average daily volume of 373,700 shares, the short-interest ratio is presently 3.8 days. Approximately 4.0% of the shares of the company are sold short. View Five Prime Therapeutics' Current Options Chain.

Some companies that are related to Five Prime Therapeutics include Merus (MRUS), Urogen Pharma (URGN), Ardelyx (ARDX), Beyondspring (BYSI), Puma Biotechnology (PBYI), Avadel Pharmaceuticals (AVDL), Viking Therapeutics (VKTX), TherapeuticsMD (TXMD), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), BioDelivery Sciences International (BDSI), OrganiGram (OGI), Satsuma Pharmaceuticals (STSA), Trillium Therapeutics (TRIL) and ProQR Therapeutics (PRQR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), Ionis Pharmaceuticals (IONS), Opko Health (OPK), Sangamo Therapeutics (SGMO), Amarin (AMRN) and Anavex Life Sciences (AVXL).

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (21.39%), Renaissance Technologies LLC (4.84%), State Street Corp (1.72%), Man Group plc (1.50%), Geode Capital Management LLC (1.42%) and AQR Capital Management LLC (1.23%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View institutional ownership trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Nuveen Asset Management LLC, Assenagon Asset Management S.A., AXA, UBS Group AG, State Street Corp, Citigroup Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Five Prime Therapeutics.

FPRX stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd., and Geode Capital Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $2.33.

Five Prime Therapeutics has a market capitalization of $84.79 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe. View additional information about Five Prime Therapeutics.

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]